Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. (XERS) filed a Form 8-K on March 6, 2025, to announce its results of operations and business highlights for the three and twelve months ended December 31, 2024. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Chicago, Illinois.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus prior periods. It serves as a notification that the Company has issued a press release containing this comparative information.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 6, 2025) for specific Q4 and full-year 2024 financial figures.
- Verify the Company's cash position and burn rate given the lack of revenue disclosure in the 8-K text.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the referenced press release.
- Check for any new debt covenants or liquidity events disclosed in the full press release.